17.30
0.22 (1.29%)
| Penutupan Terdahulu | 17.08 |
| Buka | 17.24 |
| Jumlah Dagangan | 15,478,000 |
| Purata Dagangan (3B) | 9,164,016 |
| Modal Pasaran | 46,780,059,648 |
| Harga / Pendapatan (P/E TTM) | 15.04 |
| Harga / Jualan (P/S) | 1.39 |
| Harga / Buku (P/B) | 2.21 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 27 Aug 2025 - 3 Sep 2025 |
| Hasil Dividen (DY TTM) | 1.13% |
| Margin Keuntungan | 14.71% |
| Margin Operasi (TTM) | 13.91% |
| EPS Cair (TTM) | 1.20 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 16.00% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 32.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 40.69% |
| Nisbah Semasa (MRQ) | 1.75 |
| Aliran Tunai Operasi (OCF TTM) | 2.68 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -339.13 M |
| Pulangan Atas Aset (ROA TTM) | 4.65% |
| Pulangan Atas Ekuiti (ROE TTM) | 12.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | PHARMARON | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.13 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| PHARMARON | 47 B | 1.13% | 15.04 | 2.21 |
| WUXI BIO | 115 B | - | 33.47 | 2.41 |
| SINO BIOPHARM | 102 B | 1.02% | 51.73 | 3.26 |
| INNOVENT BIO | 141 B | - | - | 10.22 |
| AKESO | 101 B | - | - | 13.96 |
| BEIGENE | 221 B | - | - | 7.89 |
|
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Core |
| % Dimiliki oleh Institusi | 30.73% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |